Form 4: Hologic Director Christiana Stamoulis Reports Acquisition of Common Stock and Stock Options

Director Christiana Stamoulis reported the acquisition of common stock and stock options in Hologic Inc. on March 7, 2024.

Summary

• On March 7, 2024, Christiana Stamoulis, a director of Hologic Inc. (HOLX), acquired 1,572 shares of common stock.
• These shares were obtained through restricted stock units that vest on the date of the 2025 Annual Meeting of Stockholders and are settled in shares of common stock on a one-for-one basis.
• Additionally, Ms. Stamoulis acquired 4,536 non-qualified stock options with an exercise price of $76.32, which become exercisable on the date of the 2025 Annual Meeting of Stockholders and expire on March 7, 2034.
• Following these transactions, Ms. Stamoulis beneficially owns 45,472 shares of Hologic common stock and 4,536 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing. The acquisition of shares by a director could be interpreted slightly positively, but it's not a major event.

Positives

• The acquisition of stock and options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The restricted stock units vest and the options become exercisable on the date of the 2025 Annual Meeting of Stockholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the actions of company directors and officers, which can influence market sentiment.

Stakeholder Impact

• The acquisition of shares by a director may have a minor positive impact on shareholder confidence.

Key Dates